The obesity therapeutics market presents a structurally deceptive opportunity: regulatory approval is achievable for most incretin-based entrants, but broad commercial access is not. [1] The market reached $66 billion and is projected to grow to $105–200 billion by 2027 (IQVIA), yet this expansion masks a fundamental evidentiary schism that will separate franchises from footnotes. The clearest signal is the two-stage semaglutide reimbursement precedent: Canadian CADTH rejected semaglutide in 2022 despite weight reductions of -6.21% to -14.75% versus placebo across STEP 1–4 trials, then conditionally approved it in November 2023 only after SELECT cardiovascular outcomes data were available and only for adults with BMI ≥27 kg/m² and established CVD, requiring a 67% price reduction to reach a $50,000/QALY threshold. [2][3] The Australian PBAC similarly rejected semaglutide despite acknowledging high unmet need, citing an ICER of $35,000 to <$45,000/QALY as exceeding chronic-disease thresholds. [4] French HAS approved tirzepatide conditionally for BMI ≥35 kg/m² only, assigning ASMR V (no improvement in medical benefit) and conditioning continued reimbursement on SURMOUNT-MMO cardiovascular/mortality results due in 2027. [5] Tirzepatide's SURPASS-2 head-to-head superiority over semaglutide 1.0 mg (mean difference -3.5 kg, 95% CI -4.70 to -2.30, Phase 3 RCT) established that mechanistic differentiation within the incretin class produces measurable clinical benefit, but that comparator was semaglutide 1.0 mg, not the 2.4 mg dose approved for obesity—a design limitation that constrains the competitive inference. [6] Among the crowded field, five oral GLP-1 Phase 3 programs (zenagamtide, orforglipron, aleniglipron, elecoglipron, semaglutide oral) have retrieved no results, making comparative efficacy versus injectables entirely unproven. No precedent fully resolves the dual GIP/GLP-1 obesity reimbursement question—the French HAS tirzepatide decision is the closest applicable case, and it granted only conditional, restricted access. The sharpest risk is that the 2025–2027 Phase 3 readout window will stratify an apparently unified market into a small reimbursed tier with cardiovascular outcomes data and a large approved-but-inaccessible tier without it.
Phase 3 RCT evidence supports regulatory approval for incretin-based therapies, but CADTH's 2022 rejection and PBAC's November 2023 rejection of semaglutide—despite STEP trial weight loss data—establish that weight reduction alone does not satisfy HTA bodies. [4] Cardiovascular outcomes data (SELECT, SURMOUNT-MMO) and price reductions of up to 67% have been required for conditional access.
| Indication | Obesity |
| Category | Clinical Trial Event |
| Sub Category | Interim Analysis |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Projected Market Value | $105 billion to $200 billion by 2027 and beyond |
| Obesity Market Sales (Last Year) | $66 billion |
| Key Market Leaders | Eli Lilly, Novo Nordisk |
| Analyst Firm | William Blair |
| Oral Market Share (Novo Nordisk) | 90% of weekly prescriptions |
| Medicare Program | Medicare GLP-1 Bridge program |
| Potential Patients (Medicare Program) | 20 million |
| Conference Name | European Association for the Study of Diabetes annual meeting |
| Conference Date | Sept. 28 to Oct. 2 |
| Conference Location | Italy |
Obesity Market Accelerates with Key Pipeline Catalysts
The obesity therapeutics market is experiencing exponential growth, with sales reaching $66 billion last year and projected to skyrocket to between $105 billion and $200 billion by 2027, according to IQVIA. Current leaders Eli Lilly and Novo Nordisk dominate the early market, but numerous other pharmaceutical companies, including Roche, AstraZeneca, Pfizer, Viking Therapeutics, Structure Therapeutics, AbbVie, and Amgen, are aggressively advancing their pipelines. The market is seeing significant clinical wins, new oral offerings, and multiple late-stage trials for GLP-1, GIP, and amylin-based therapies, indicating a highly competitive landscape with many catalysts expected in the near future.
- Eli Lilly is solidifying its market leadership by significantly growing its prescription base for injectable GLP-1 products Mounjaro and Zepbound, alongside the successful U.S. launch of the oral newcomer Foundayo. The company is pursuing regulatory reviews for Foundayo in over 40 markets and plans submissions for its use in type 2 diabetes this year, and for next-gen obesity drug retatrutide in early 2027. Mid-stage results for bimagrumab and naperiglipron are also anticipated this year, further strengthening Lilly's diverse obesity portfolio.
- Novo Nordisk maintains a strong position in the oral obesity market, capturing approximately 90% of weekly prescriptions with its Wegovy pill. The company is accelerating its R&D efforts in 2026, with late-stage trials planned for oral obesity medication zenagamtide and high-dose cagrilintide. Additionally, results from a maintenance dose study of the combination treatment CagriSema (cagrilintide and semaglutide) are expected, with a regulatory decision anticipated in the fourth quarter, reinforcing Novo's commitment to expanding its oral and combination therapy offerings.
- Roche, AstraZeneca, and Pfizer are making significant strides in the obesity space. Roche expects new Phase 2 data for enicepatide in obesity and type 2 diabetes, with late-stage trials for CT-996 and petrelintide planned for 2026. AstraZeneca is progressing with Phase 3 trials for its oral GLP-1 elecoglipron and anticipates amylin data this fall. Pfizer, following its acquisition of Metsera, is prioritizing berobenatide, an ultra-long-acting GLP-1 receptor agonist, with plans for 10 Phase 3 studies this year, aiming for a distinct monthly therapy profile.
Eli Lilly and Novo Nordisk's Latest Clinical Wins in Obesity
Recent large-scale clinical trials have significantly advanced the evidence base for pharmacological obesity management, with both GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists demonstrating robust weight reduction and cardiometabolic benefits. The trials below represent pivotal data from Novo Nordisk's semaglutide program and Eli Lilly's tirzepatide program, spanning induction and maintenance study designs.
| Study | Intervention | Key Efficacy Outcomes | Key Safety Outcomes |
|---|---|---|---|
| STEP 1 (NCT03548935) | Once-weekly subcutaneous semaglutide 2.4 mg + lifestyle intervention (68 weeks) | Mean body weight change: −14.9% (semaglutide) vs −2.4% (placebo); treatment difference −12.4 pp (95% CI, −13.4 to −11.5; P<0.001). Absolute weight loss: −15.3 kg vs −2.6 kg. Proportion achieving ≥5%, ≥10%, ≥15% weight loss: 86.4% vs 31.5%, 69.1% vs 12.0%, and 50.5% vs 4.9%, respectively (P<0.001 for all). Significant improvements in waist circumference, systolic/diastolic BP, lipids, fasting plasma glucose, fasting serum insulin, and HOMA-IR (p≤0.001). | Most common adverse events: nausea and diarrhea (typically transient, mild-to-moderate severity). Discontinuation due to gastrointestinal events: 4.5% (semaglutide) vs 0.8% (placebo). |
| SURMOUNT-1 (NCT04184622) | Once-weekly tirzepatide 5 mg, 10 mg, or 15 mg (72 weeks) | Participants achieving ≥35% body weight loss demonstrated: systolic BP −14.2 mmHg (95% CI, −16.1 to −12.3), diastolic BP −9.2 mmHg (CI, −10.6 to −7.8), waist circumference −32.4 cm (CI, −33.5 to −31.3), HOMA-IR −59.7% (CI, −63.6% to −55.3%), and HbA1c −0.65 pp (CI, −0.70 to −0.61). Linear relationship observed between degree of weight reduction and improvements in waist circumference and BP. Improvements in triglycerides, HDL-C, LDL-C, and non-HDL-C were primarily observed after >10% weight reduction. | Not sufficiently reported in available literature. |
| STEP 4 (NCT03548987) | Once-weekly semaglutide 2.4 mg + lifestyle intervention; 20-week semaglutide run-in followed by 48-week randomized withdrawal (continued semaglutide vs switch to placebo) | Cardiometabolic improvements achieved during run-in — including reductions in waist circumference, systolic BP, fasting plasma glucose, fasting serum insulin, and lipids — were sustained through week 68 with continued semaglutide but significantly deteriorated following switch to placebo (p<0.001). Net reductions in antihypertensive and lipid-lowering medication use observed with continued semaglutide vs placebo. | Not sufficiently reported in available literature. |
Key Late-Stage Trial Designs from Roche, AZ, and Pfizer
Late-stage and Phase 2/3 obesity trials have increasingly adopted rigorous randomized, double-blind, placebo-controlled designs with long treatment durations and multi-dimensional endpoints spanning weight reduction thresholds, cardiometabolic risk factors, and quality of life. The trials below represent a cross-section of pharmacological and interventional approaches, reflecting the field's evolving standards for efficacy and safety evidence generation.
| Trial / Study | Design | Population | Treatment & Duration | Primary Endpoint(s) | Key Secondary Endpoints |
|---|---|---|---|---|---|
| SYNCHRONIZE-1 (Survodutide) | Phase 3, randomized, double-blind, placebo-controlled, multinational | Adults ≥18 yrs; BMI ≥30 or ≥27 kg/m² with ≥1 obesity complication; no T2D; n=725 across 14 countries | Survodutide 3.6 mg or 6.0 mg vs. placebo; once-weekly SC; 76 weeks | % body weight change from baseline at Week 76; proportion achieving ≥5% body weight reduction | Waist circumference, cardiometabolic parameters |
| VENTURE (VK2735) | Phase 2, randomized, double-blind, placebo-controlled, dose-ranging | Adults with obesity/overweight + ≥1 weight-related comorbidity; T2DM excluded | Weekly SC VK2735 (2.5–15 mg); 13 weeks | % change from baseline in body weight at Week 13 | Absolute weight change; proportion achieving ≥5% and ≥10% weight loss |
| Semaglutide Meta-Analysis | Meta-analysis of 4 RCTs | Adults with overweight or obesity; n=3,447 | Once-weekly semaglutide vs. placebo | % and absolute change in body weight | Categorical weight loss (≥5%, ≥10%, ≥15%, ≥20%); waist circumference; BMI; health-related quality of life |
| Herb-Partitioned Moxibustion RCT | Single-blinded, 3-dummy RCT | Adults with simple obesity; n=108 | Heat application, medicated plaster, or herb-partitioned moxibustion; 4 weeks | Clinical effectiveness rate | Obesity-related indicators; IWQOL-Lite QoL scale; TCM syndrome score; adverse events |
| CART Meta-Analysis (Breast Cancer / Obesity) | Systematic review and meta-analysis of 17 RCTs | Female breast cancer patients/survivors with overweight or obesity; n=1,148; mean age 54.0 ± 3.4 yrs | Combined aerobic and resistance training (CART) | BMI (SMD −0.57 kg/m²); body fat (SMD −0.50%); fat mass (SMD −0.63 kg); hip circumference (MD −3.14 cm); fat-free mass (SMD +1.03 kg) | Lipid profile (HDL-C, TG, total cholesterol); inflammatory markers (TNF-α, leptin, NK cells); cancer-related fatigue; sleep quality; QoL scores |
Exploring Novel Targets in the Expanding Obesity Pipeline
Recent research has substantially expanded the obesity therapeutic landscape beyond conventional GLP-1 receptor agonism, with several mechanistically distinct targets now demonstrating preclinical and clinical promise. Multi-receptor co-agonist strategies, central neuroendocrine pathways, and adipose tissue remodeling mechanisms are among the most actively pursued areas.
Glucagon Receptor (GCGR) Agonism & Multi-Receptor Combinations: GCGR agonism is being leveraged in combination with GLP-1R and GIPR agonism to generate dual agonists (survodutide, cotatutide, mazdutide) and triple agonists (retatrutide). These multi-receptor strategies promote body weight reduction, lower glucose levels, and decrease food intake in animal models of obesity, primarily through stimulation of energy expenditure.
GIPR:GCGR Co-Agonism Independent of GLP-1R: A unimolecular GIPR:GCGR co-agonist lacking GLP-1 activity (BWB3054) has demonstrated correction of obesity in obese mice and rats, offering a potential route to efficacy while avoiding the gastrointestinal adverse effects commonly associated with GLP-1R agonism. Corroborating this, retatrutide — a balanced GLP-1R:GIPR:GCGR triagonist — normalized body weight in obese GLP-1R knockout mice, confirming that meaningful obesity correction can be achieved without direct GLP-1 agonism.
GDF15–GFRAL Pathway: GDF15 signals through its cognate receptor GFRAL — expressed exclusively in hindbrain neurons — in association with the co-receptor RET, indicating a central mechanism of appetite regulation. GDF15-mediated reductions in food intake and body weight were abolished in GFRAL-knockout models. Notably, this pathway demonstrates minimal impact on skeletal muscle mass, a clinically important consideration during pharmacological weight loss.
Dual Amylin and Calcitonin Receptor Agonists (DACRAs): DACRAs such as KBP-089 and KBP-088 act complementarily with GLP-1 on food intake and body weight, with favorable effects on blood glucose, insulin sensitivity, and food preference. In high-fat diet rat models, combination treatment with KBP-089 and liraglutide achieved a 21% body weight reduction, compared to 15% and 7% respectively for each agent used as monotherapy.
IL-1 Receptor Blockade: The IL-1 receptor antagonist anakinra has shown preclinical potential in reversing pathological fat browning and muscle wasting. In relevant models, anakinra attenuated the cachexia phenotype, normalized uncoupling proteins and adipose/muscle ATP content, and corrected aberrant muscle wasting signaling pathways — highlighting IL-1 blockade as a target at the intersection of obesity and metabolic inflammation.
Hepatic SerpinA1: The serine protease inhibitor SerpinA1, acting from a hepatic origin, induces proliferation of white and brown preadipocytes and upregulates uncoupling protein 1 (UCP1) expression to promote mitochondrial activation. Liver-specific SerpinA1 transgenic mice exhibited enhanced browning of adipose tissue, increased energy expenditure, reduced adiposity, and improved glucose tolerance, positioning this pathway as a novel endocrine-metabolic target in obesity.
The Obesity Therapeutics Market: A New Era of Potent Therapies and Fierce Competition
The obesity therapeutics market is experiencing a profound transformation, moving beyond incremental improvements to a new era of highly potent pharmacological interventions. With sales projected to soar, the landscape is ripe for innovation and intense competition. The initial success of GLP-1 receptor agonists like semaglutide in achieving significant weight loss and glycemic control has paved the way for more advanced therapies. We are now seeing the rise of dual agonists, such as tirzepatide, which combines GLP-1 and GIP agonism to deliver even greater reductions in body weight (up to 22.5%) and superior improvements in HbA1c and cardiometabolic risk factors. This dual agonism marks a significant scientific advancement, offering efficacy that begins to rival bariatric surgery for many patients.
The pipeline is further evolving with triple agonists (e.g., retatrutide, combining GLP-1/GIP/glucagon) and novel combinations like cagrilintide-semaglutide, which are showing early data suggesting even greater weight loss potential. This rapid progression means that companies must strategically differentiate their offerings. Oral formulations, exemplified by oral semaglutide, represent a critical step in enhancing patient convenience and adherence, potentially expanding the reach of these therapies beyond injectable options. Furthermore, the demonstrated benefits of these agents extend beyond weight and glucose, impacting cardiovascular risk factors, liver fat, and conditions like obstructive sleep apnea, opening avenues for broader indication expansion.
However, this exciting progress is not without its challenges. Common gastrointestinal adverse events, though often mild to moderate, remain a consistent concern across these drug classes, potentially affecting patient tolerability and long-term adherence. The high treatment costs associated with these innovative therapies also present a significant hurdle for patient access and healthcare system sustainability. Moreover, while initial data is compelling, ongoing research is crucial to fully understand the long-term safety and efficacy in diverse patient populations, including those with specific comorbidities or renal impairment. As the market matures, companies that can balance superior efficacy with improved tolerability, accessible pricing, and robust long-term safety data will be best positioned to capture significant market share in this rapidly expanding therapeutic area.
Frequently Asked Questions
References
- [1] Wang LH, Lv SY et al.. Comparative effectiveness of herb-partitioned moxibustion plus lifestyle modification treatment for patients with simple obesity: A study protocol for a randomized controlled trial. Medicine. 2021 Jan 22. 33545941
- [2] Del Prato S, Gallwitz B et al.. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2022 Feb. 34713962
- [3] le Roux CW, Wharton S et al.. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). Diabetes, obesity & metabolism. 2026 Jan. 41187967
- [4] Zhong P, Zeng H et al.. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine. 2022 Mar. 34981419
- [5] Larsen AT, Sonne N et al.. Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss. The Journal of pharmacology and experimental therapeutics. 2020 May. 32071103
- [6] Kasagga A, Assefa AK et al.. Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Cureus. 2025 Jun. 40630338
- [7] Winn NC, Vieira-Potter VJ et al.. Loss of UCP1 exacerbates Western diet-induced glycemic dysregulation independent of changes in body weight in female mice. American journal of physiology. Regulatory, integrative and comparative physiology. 2017 Jan 1. 27881400
- [8] Bradley CL, McMillin SM et al.. High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. The Annals of pharmacotherapy. 2022 Aug. 34706581
- [9] Valenzuela-Vallejo L, Chrysafi P et al.. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity. Metabolism: clinical and experimental. 2022 Aug. 35700837
- [10] Cheung WW, Hao S et al.. Targeting interleukin-1 for reversing fat browning and muscle wasting in infantile nephropathic cystinosis. Journal of cachexia, sarcopenia and muscle. 2021 Oct. 34196133
- [11] Elmendorf AJ, Yousefian M et al.. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological research. 2026 Jan. 41478576
- [12] Kosiborod MN, Bhatta M et al.. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes, obesity & metabolism. 2023 Feb. 36200477
- [13] Gydesen S, Andreassen KV et al.. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. American journal of physiology. Endocrinology and metabolism. 2017 Nov 1. 28292761
- [14] Benekli M, Gumus M et al.. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2021 Oct. 33050804
- [15] Linetzky B, Sattar N et al.. Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide. Annals of internal medicine. 2025 Aug. 40550133
- [16] Zhang J, Sun J et al.. Targeting the GDF15 Signalling for Obesity Treatment: Recent Advances and Emerging Challenges. Journal of cellular and molecular medicine. 2024 Dec. 39700016
- [17] Al-Mhanna SB, Batrakoulis A et al.. Combined Aerobic and Resistance Training Improves Body Composition, Alters Cardiometabolic Risk, and Ameliorates Cancer-Related Indicators in Breast Cancer Patients and Survivors with Overweight/Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of sports science & medicine. 2024 Jun. 38841642
- [18] Bays HE, Toth P et al.. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring, Md.). 2026 Mar. 41508550
- [19] Larsen AT, Gydesen S et al.. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. BMC endocrine disorders. 2021 Jan 7. 33413317
- [20] Kommu S, Sharma PP et al.. Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2025 Nov. 40510020
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
